Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Wednesday, 1 May 2013
- AstraZeneca and MedImmune are out in force at BIO 2013 This year team members from AstraZeneca and MedImmume business development attended over 500 partnering meetings at BIO in Chicago and took part in several high profile speaker panels.
- Wednesday, 24 April 2013
- Alchemia Announces Multi-Target Drug Discovery Collaboration with AstraZeneca on VAST Discovery Platform Alchemia Limited (ASX:ACL), a drug discovery and development company, today announces that it has signed a multi-target, drug discovery collaboration with AstraZeneca PLC.
- Monday, 22 April 2013
- Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca Cambridge, UK, 22 April 2013: Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.